ArticlePhysics and imaging in radiation oncology2026
A novel approach for spot boosting selection and treatment plan optimization to enhance prompt gamma monitoring of proton therapy.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Purpose: Despite continuous progress, proton therapy remains challenged by delivery uncertainties. Material and Methods: A prostate and a head-and-neck plans were generated with a research version of RayStation (RaySearch, Sweden) treatment planning system. A detailed workflow was implemented to select candidate spots to artificially increase the number of protons (boosting) delivered according to specific criteria. Two boosting modalities were applied: (1) assigning a fixed number of protons per boosted spot; (2) maximizing the number of protons, given a lower bound. Reoptimized, boosted plans were compared to the initial one in terms of dose, dose-averaged linear-energy-transfer (LET), LET-weighted dose and robustness. Results: Boosted plans preserved target coverage and normal tissue sparing until a boost level of around 7 × 10 Conclusions: Spot boosting is a feasible approach to enhance monitoring with secondary radiation, like PG, without compromising the plan quality. Its integration into clinics could enable an improved delivery quality assurance and a more precise proton therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.